Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MODIFY study of depemokimab in at-risk type 2 asthma
CTR20263030Phase 4Active
- Sponsor
- GSK
- Start
- Apr 2026
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 4 trial of depemokimab in Th2 asthma (Th2), sponsored by GSK. Started Apr 2026; status: active.
02
Drugs
depemokimab
03
Conditions
Th2 asthma (Th2)
Beyond the preview
Go deeper on CTR20263030.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20263030.